Myrtle Potter biography
Myrtle Stephens Potter is Chairman of the Board of the Company. Ms. Potter has served as a member of the Board since September 2018 and has served as the Chairman of the Board since November 2018. Ms. Potter has served as Vant Operating Chair of Roivant Sciences, Inc., a wholly-owned subsidiary of RSL, since July 2018. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences consulting firm, in September 2005, and served as the Chief Executive Officer until June 2018. From August 2009 until December 2014, Ms. Potter served as Founder and Chief Executive Officer of Myrtle Potter Media, Inc., a consumer healthcare company. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to that, Ms. Potter held various positions, including President, Cardiovascular/Metabolics at Bristol-Myers Squibb and a vice president at Merck & Co. Ms. Potter currently serves on the boards of directors of Axovant Gene Therapies Ltd., Urovant Sciences Ltd., Arbutus Biopharma Corporation and Axsome Therapeutics, Inc., each a pharmaceutical company, Liberty Mutual Holding Company Inc., a diversified global insurance company, and a number of privately held companies. Ms. Potter previously served on the boards of directors of INSMED Incorporated, a biopharmaceutical company, from December 2014 to November 2018, Rite Aid Corporation, a leading drugstore chain, from December 2013 to October 2018, Everyday Health, Inc., a leading provider of digital health and wellness solutions, from October 2010 until its acquisition in December 2016, and Amazon.com, Inc., a leading e-commerce company, from 2004 to 2009. Ms. Potter earned her B.A. from the University of Chicago.
What is the salary of Myrtle Potter?
As the Chairman of the Board of Myovant Sciences Ltd, the total compensation of Myrtle Potter at Myovant Sciences Ltd is $343,529. There are 7 executives at Myovant Sciences Ltd getting paid more, with Lynn Seely having the highest compensation of $6,222,670.
